Element Pointe Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-60,310
Closed -$3.69M 88
2021
Q4
$3.69M Sell
60,310
-20,175
-25% -$1.39M 1.14% 15
2021
Q3
$6.01M Sell
80,485
-1,068
-1% -$89.6K 2.03% 10
2021
Q2
$7.1M Buy
81,553
+4,228
+5% +$359K 2.15% 9
2021
Q1
$6.86M Buy
77,325
+17,607
+29% +$1.75M 2.3% 8
2020
Q4
$5.57M Buy
59,718
+38,349
+179% +$3.06M 2.07% 10
2020
Q3
$1.36M Buy
21,369
+16,025
+300% +$939K 0.61% 25
2020
Q2
$278K Buy
+5,344
New +$229K 0.14% 78

Other funds holding ARKG

Element Pointe Advisors's ARKG Position: Q1 2022 in Review

Element Pointe Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 60,310 shares — an estimated $3.69M sold.

Element Pointe Advisors first reported a position in ARKG in Q2 2020 and held it in 7 quarters. The position peaked at $7.1M in Q2 2021. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

  • Element Pointe Advisors reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
  • Element Pointe Advisors sold 60,310 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $3.69M.
  • Element Pointe Advisors first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 7 quarters.
  • Element Pointe Advisors's ARK Genomic Revolution ETF position peaked at $7.1M in Q2 2021.
  • 387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Element Pointe Advisors's 13F filing for Q1 2022, filed 11 May 2022.